Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 21, 2007
Ovarian metastases in early-stage cervical cancer (IA2-IIA): a multicenter retrospective study of 1965 patients (a Cooperative Task Force study)F Landoni, V Zanagnolo, L Lovato-Diaz, et al.
Anticancer Research|July 1, 1997
Prognostic factors in metastatic breast cancer patients obtaining objective response or disease stabilization after first-line chemotherapy with epirubicin. Evidence for a positive effect of maintenance hormonal therapy on overall survivalA Berruti, P Zola, T Buniva, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trialL Dogliotti, A Berruti, T Buniva, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 23, 2012
The need for accredited training in gynaecological oncology: a report from the European Network of Young Gynaecological Oncologists (ENYGO)R Manchanda, M Godfrey, L A Wong-Taylor, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2001
Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group studyH C Wagenaar, S Pecorelli, C Mangioni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 3, 2009
A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative StudyA A Lissoni, N Colombo, A Pellegrino, et al.
Gynecologic Oncology|May 11, 2023
Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancerI Vergote, E Van Nieuwenhuysen, A Casado, et al.
Journal of the National Cancer Institute|October 13, 2010
Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxelP Hoskins, I Vergote, A Cervantes, et al.
British Journal of Cancer|February 9, 2023
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum lineN Colombo, A Gadducci, J Sehouli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 25, 2003
Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer GroupF H van Wijk, M S Aapro, G Bolis, et al.
Pageof 8